Breast cancer (BC) is the most common malignant tumor in women. Between 20 % and 30
% of patients develop metastases from BC, 50 % of them in the liver. The mean survival
rate reported in patients with liver metastases from BC (LMBC) ranges from 3 to 29
months. The role of surgery in LMBC is not clearly defined. The objective of the present
study was to determine the long-term survival and disease-free survival of patients
undergoing surgery for LMBC and to identify the patients who most likely benefit from
surgery.This retrospective multicenter cohort study included all consecutive patients
undergoing LMBC surgery at the participating European centers from January 1, 2010,
to December 31, 2015. The ClinicalTrials.gov ID is NCT04817813.A hundred women (mean
age 52.6 years) undergoing LMBC surgery were included. Five-year disease-free survival
was 29 %, and 5-year overall survival was 60 %. Median survival after BC surgery was
12.4 years, and after LMBC surgery, 7 years. Patients with ECOG 1, ASA score I-II,
metachronous LMBC, positive hormone receptors, and who had received neoadjuvant and
adjuvant hormone treatment obtained the best overall and disease-free survival results.In
cases of correct patient selection and as part of a comprehensive onco-surgical strategy,
surgery for LMBC improves overall long-term survival. In our series, certain factors
were linked to better disease-free and overall survival; consideration of these factors
could improve the selection of the best candidates for LMBC surgery.NCT04817813.
